Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04343586 · ClinicalTrials.gov registry record · NA
Blue Light Phototherapy
A NA study of Psoriasis Vulgaris and Grover's Disease, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT04343586 is a NA study of Psoriasis Vulgaris and Grover's Disease that has completed, run by Northwestern University. The registered enrollment target is 11 participants, below the 90-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04343586, a NA study of Psoriasis Vulgaris and Grover's Disease, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.
Conditions Studied
Interventions
- DEVICE Blue light phototherapy
Study Locations (1)
Illinois
- Northwestern University Department of Dermatology - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2022-09-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04343586
The ClinicalTrials.gov registry entry for NCT04343586 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (88% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Psoriasis Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Blue light phototherapy is the first listed.
NCT04343586 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04343586 about?
NCT04343586 is a clinical study titled "Blue Light Phototherapy". This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.
What is the current status of trial NCT04343586?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2020-09-01. Estimated completion is 2022-09-22.
What conditions does trial NCT04343586 study?
This clinical trial studies the following conditions: Psoriasis Vulgaris, Grover's Disease.
What interventions are being tested in trial NCT04343586?
The interventions under investigation include: Blue light phototherapy (DEVICE).
Who is sponsoring clinical trial NCT04343586?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04343586 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Correction of Psoriatic T Cell Signatures by Deucravacitinib
RECRUITING · Phase 4
-
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
RECRUITING · Phase 3
-
Use of Botulinum Toxin to Treat Psoriasis
COMPLETED · Phase 1
-
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
COMPLETED · Phase 2
-
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris
COMPLETED · Phase 1
-
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.